Home LiteratureArticle Details
PMID: 22399094 Published · ppublish English Journal Article

Residual vectors for Alzheimer disease diagnosis and prognostication.

Brain and behavior ·Vol. 1 ·No. 2 ·2011-11-00 ·Pages 142-52

Clark DG, Alzheimer Disease Neuroimaging Initiative

Abstract

Alzheimer disease (AD) is an increasingly prevalent neurodegenerative condition and a looming socioeconomic threat. A biomarker for the disease could make the process of diagnosis easier and more accurate, and accelerate drug discovery. The current work describes a method for scoring brain images that is inspired by fundamental principles from information retrieval (IR), a branch of computer science that includes the development of Internet search engines. For this research, a dataset of 254 baseline 18-F fluorodeoxyglucose positron emission tomography (FDG-PET) scans was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI). For a given contrast, a subset of scans (nine of every 10) was used to compute a residual vector that typified the difference, at each voxel, between the two groups being contrasted. Scans that were not used for computing the residual vector (the remaining one of 10 scans) were then compared to the residual vector using a cosine similarity metric. This process was repeated sequentially, each time generating cosine similarity scores on 10% of the FDG-PET scans for each contrast. Statistical analysis revealed that the scores were significant predictors of functional decline as measured by the Functional Activities Questionnaire (FAQ). When logistic regression models that incorporated these scores were evaluated with leave-one-out cross-validation, cognitively normal controls were discerned from AD with sensitivity and specificity of 94.4% and 84.8%, respectively. Patients who converted from mild cognitive impairment (MCI) to AD were discerned from MCI nonconverters with sensitivity and specificity of 89.7% and 62.9%, respectively, when FAQ scores were brought into the model. Residual vectors are easy to compute and provide a simple method for scoring the similarity between an FDG-PET scan and sets of examples from a given diagnostic group. The method is readily generalizable to any imaging modality. Further interdisciplinary work between IR and clinical neuroscience is warranted.

Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Clark David Glenn
Alzheimer Disease Neuroimaging Initiative
References (20)
20 references, click to expand
  1. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    N Engl J Med. 2005 Jun 9;352(23):2379-88 PMID: 15829527
  2. Resting-state functional connectivity reflects structural connectivity in the default mode network.
    Cereb Cortex. 2009 Jan;19(1):72-8 PMID: 18403396
  3. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
    Brain. 2007 Oct;130(Pt 10):2616-35 PMID: 17704526
  4. Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database.
    Neuroimage. 2011 May 15;56(2):766-81 PMID: 20542124
  5. Automated image registration: I. General methods and intrasubject, intramodality validation.
    J Comput Assist Tomogr. 1998 Jan-Feb;22(1):139-52 PMID: 9448779
  6. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.
    AJNR Am J Neuroradiol. 2010 Feb;31(2):347-54 PMID: 20075088
  7. A default mode of brain function.
    Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82 PMID: 11209064
  8. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  9. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
    Neuropsychopharmacology. 2005 Jun;30(6):1204-15 PMID: 15742005
  10. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI.
    Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4637-42 PMID: 15070770
  11. Alzheimer disease in the US population: prevalence estimates using the 2000 census.
    Arch Neurol. 2003 Aug;60(8):1119-22 PMID: 12925369
  12. Comparing predictors of conversion and decline in mild cognitive impairment.
    Neurology. 2010 Jul 20;75(3):230-8 PMID: 20592257
  13. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
    J Nucl Med. 2005 Oct;46(10):1625-32 PMID: 16204712
  14. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?
    Neurology. 2003 Apr 22;60(8):1374-7 PMID: 12707450
  15. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.
    J Nucl Med. 2007 Jul;48(7):1129-34 PMID: 17574982
  16. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Lancet Neurol. 2007 Jun;6(6):501-12 PMID: 17509485
  17. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
    J Nucl Med. 1995 Jul;36(7):1238-48 PMID: 7790950
  18. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.
    JAMA. 2001 Nov 7;286(17):2120-7 PMID: 11694153
  19. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
    Neurology. 2004 Aug 24;63(4):651-7 PMID: 15326237
  20. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
    Neurobiol Aging. 2011 Jul;32(7):1207-18 PMID: 19660834
Article Info
Journal
Brain and behavior
Abbr.
Brain Behav
ISSN
2162-3279
Published
2011-11-00
Pages
142-52
Language
English
Region
United States
NLM ID
101570837
PMCID
PMC3236543
Grants
NIA NIH HHS · K01 AG030514 · United States
NIA NIH HHS · P30 AG010129 · United States
NIA NIH HHS · U01 AG024904 · United States
NIA NIH HHS · U19 AG010483 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]